AR010341A1 - Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion - Google Patents

Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion

Info

Publication number
AR010341A1
AR010341A1 ARP970105775A ARP970105775A AR010341A1 AR 010341 A1 AR010341 A1 AR 010341A1 AR P970105775 A ARP970105775 A AR P970105775A AR P970105775 A ARP970105775 A AR P970105775A AR 010341 A1 AR010341 A1 AR 010341A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
construction
preparing
pharmaceutical composition
vector
Prior art date
Application number
ARP970105775A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR010341A1 publication Critical patent/AR010341A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

Constructo de ácido nucleico que comprende los componentes siguientes: al menos un primer gen estructural que codifica un compuesto activo; al menos unsegundo gen estructural que codifica una proteína de factor de transcripcion; y al menos unasec uencia que se fija a la proteína de factor de transcripcions yal menos una secuencia promotora; en el cual cada secuencia de activacion activa la expresion de un gen estructural y la expresion de la proteína defactor de transcripcion;proceso para preparar dicho constructo, vector y célula que lo comprenden y uso del mismo, y una composicion farmacéutica quecomprende el constructo de ácido nucleico y un método para preparar la composicion farmacéutica.
ARP970105775A 1996-12-11 1997-12-09 Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion AR010341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19651443A DE19651443A1 (de) 1996-12-11 1996-12-11 Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme

Publications (1)

Publication Number Publication Date
AR010341A1 true AR010341A1 (es) 2000-06-07

Family

ID=7814335

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105775A AR010341A1 (es) 1996-12-11 1997-12-09 Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion

Country Status (15)

Country Link
US (3) US6383785B1 (es)
EP (1) EP0848061A3 (es)
JP (1) JPH11176A (es)
KR (1) KR19980064289A (es)
CN (1) CN1191898A (es)
AR (1) AR010341A1 (es)
AU (1) AU738344B2 (es)
BR (1) BR9705527A (es)
CA (1) CA2224334A1 (es)
CZ (1) CZ397797A3 (es)
DE (1) DE19651443A1 (es)
HU (1) HUP9702377A3 (es)
PL (1) PL323657A1 (es)
RU (1) RU2197993C2 (es)
TR (1) TR199701579A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
AU6636800A (en) * 1999-08-13 2001-03-13 Proteinix Company Heat shock fusion-based vaccine system
IL132446A0 (en) * 1999-10-18 2001-03-19 Genena Ltd A method for establishing connections between genes
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
AU2046801A (en) * 1999-11-23 2001-06-04 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2601141T3 (es) 2001-09-13 2017-02-14 California Institute Of Technology Método para la expresión de moléculas de ARN pequeño dentro de una célula
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
JP2005253385A (ja) * 2004-03-12 2005-09-22 Shin Sasaki 転写因子結合領域導入プロモータを含む発現ベクター及び転写因子重発現システムによる遺伝子発現方法
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
EP2167130A2 (en) * 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
NZ588671A (en) * 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2744289A1 (en) * 2008-11-25 2010-06-03 Otsuka Pharmaceutical Co., Ltd. Stem cell for therapeutic use which is derived from human monocyte, and method for inducing same
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
WO2014127148A1 (en) * 2013-02-14 2014-08-21 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
JP2016519570A (ja) 2013-03-14 2016-07-07 エペイウス バイオテクノロジーズ コーポレイション 改善されたチミジンキナーゼ遺伝子
WO2016048994A2 (en) * 2014-09-23 2016-03-31 President And Fellows Of Harvard College Systems and methods of cell-free protein synthesis in droplets and other compartments
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683227B2 (en) * 1992-08-26 1997-11-06 Bioscience 2002 Llc Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
ES2140359T1 (es) * 1993-06-14 2000-03-01 Basf Ag Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina.
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
WO1996006938A1 (de) * 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung

Also Published As

Publication number Publication date
CA2224334A1 (en) 1998-06-11
EP0848061A3 (en) 2004-02-18
CN1191898A (zh) 1998-09-02
AU738344B2 (en) 2001-09-13
US20020151049A1 (en) 2002-10-17
EP0848061A2 (en) 1998-06-17
TR199701579A3 (tr) 1998-06-22
TR199701579A2 (xx) 1998-06-22
DE19651443A1 (de) 1998-06-18
RU2197993C2 (ru) 2003-02-10
HUP9702377A2 (hu) 1998-09-28
KR19980064289A (ko) 1998-10-07
AU4836297A (en) 1998-06-18
CZ397797A3 (cs) 1998-06-17
PL323657A1 (en) 1998-06-22
US20030008398A1 (en) 2003-01-09
JPH11176A (ja) 1999-01-06
US6383785B1 (en) 2002-05-07
HU9702377D0 (en) 1998-03-02
HUP9702377A3 (en) 2004-06-28
BR9705527A (pt) 1999-10-05
US6482618B2 (en) 2002-11-19
MX9710007A (es) 1998-12-31

Similar Documents

Publication Publication Date Title
AR010341A1 (es) Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion
STAVNEZER et al. Synthesis of a mouse immunoglobulin light chain in a rabbit reticulocyte cell-free system
AR024699A1 (es) Polipeptidos hibridos con propiedades farmacocineticas aumentadas
DE69730218D1 (de) Fusogene liposomen
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
AR007737A1 (es) Un derivado de un peptido soluble, un procedimiento para su preparacion, una porcion polipeptidica del mismo, un polimero de adn, un vector de expresionreplicable, una celula huesped, un elemento peptidico modificado que se une a la membrana, una composicion farmaceutica que comprende dicho derivado y el uso
PT695360E (pt) Adenovirus recombinantes deficientes, para a terapia genica de tumores
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
BR112022016657A2 (pt) Células car-t bcma com atividades melhoradas
DE69635895D1 (de) Antigen presentierende bläschen, die von zellen ableiten
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
AR033834A1 (es) Una proteina de fusion para liberar un compuesto a una celula, un metodo para liberar dicho compuesto, un metodo para identificar un peptido penetrador de membranas, y el uso de una proteina de fusion para la manufactura de un agente
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
DE69837754D1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
Weisdorf The role of second transplants for leukemia
BR0015236A (pt) Métodos de inicialização para sistemas catalisadores múltiplos
Takagi et al. Evidence for exclusive biosynthesis in vivo of serum albumin by bound polysomes of rat liver
BR112023007922A2 (pt) Método de geração de linfócitos infiltrantes no tumor, método para expandir uma população de linfócitos infiltrantes no tumor (tils) ou linfócitos infiltrantes na medula (mils) e métodos de tratamento de câncer em um sujeito
PT894141E (pt) Proteinas hibridas que formam heterodimeros
BR9811850A (pt) Expressão recombinante de peptìdeo c de insulina
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta

Legal Events

Date Code Title Description
FA Abandonment or withdrawal